Retapamulin [224452-66-8]
Cat# B2019-10mg
Size : 10mg
Brand : APExBIO Technology
- Home
- Lab Reagents
- Antibiotics
- Retapamulin
Retapamulin
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Retapamulin is a pleuromutilin antibiotic [1].
Retapamulin is developed for topical treatment of skin infections which is mainly caused by gram-positive organisms, β-hemolytic streptococci and coagulase-negative staphylococci. Retapamulin is especially used against those drug resistance strains. In the in vitro studies, retapamulin demonstrates potent activity and a broad spectrum. It shows excellent antimicrobial activities against S. aureus, S. epidermidis, S. saprophyticus, S. pyogenes, S. agalactiae and Viridans group streptococci with MIC50 values of 0.06μg/ml, 0.06μg/ml, 0.12μg/ml, 0.008μg/ml, 0.016μg/ml and 0.03μg/ml, respectively. Retapamulin plays its antibiotic role through binding to a unique site of the bacterial ribosome [1, 2].
References:
[1] Jones R N, Fritsche T R, Sader H S, et al. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrobial agents and chemotherapy, 2006, 50(7): 2583-2586.
[2] Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrobial agents and chemotherapy, 2006, 50(11): 3882-3885.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 517.76 |
| Cas No. | 224452-66-8 |
| Formula | C30H47NO4S |
| Solubility | insoluble in H2O; ≥114.8 mg/mL in EtOH; ≥16.15 mg/mL in DMSO |
| Chemical Name | (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)thio)acetate |
| SDF | Download SDF |
| Canonical SMILES | O[C@H]([C@](C)(C=C)C1)[C@H](C)[C@]2(CCC3=O)[C@]3(19)[C@@]([C@@H]1OC(CSC4C[C@](CC5)(19)N(C)[C@]5(19)C4)=O)(C)[C@H](C)CC2 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | Strains of anaerobic bacteria |
| Preparation method | The solubility of this compound in DMSO is ≥16.15 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Reacting condition | 512 mg/L |
| Applications | Retapamulin (<2 mg/L) inhibits 37/52 (71%) B. fragile strains and 85/87 (98%) other Gram-negative bacteria. Retapamulin is more effective against C. acnes and anaerobic gram-positive cocci than clindamycin, metronidazole and ceftriaxone. |
| References: [1]. Odou MF, Muller C, Calvet L, Dubreuil L. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother. 2007 Apr;59(4):646-51. Epub 2007 Mar 9. PubMed PMID:17350985. | |